INCA1: A Potential Drug Target for Neurological Disorders (G388324)

Target Name: INCA1

NCBI ID: G388324

INCA1

INCA1: A Potential Drug Target for Neurological Disorders

INCA1 (INCA1 variant 1) is a protein that is expressed in the nervous system and has been shown to play a role in the development and progression of various neurological disorders, including Alzheimer's disease. The protein is a key component of the huntingtin gene family, which is known for its role in the development of neurodegenerative diseases.

Recent studies have identified INCA1 as a potential drug target for the treatment of Alzheimer's disease and other neurological disorders. The protein has been shown to interact with a variety of different molecules, including the beta-amyloid protein that is thought to contribute to the development of Alzheimer's disease.

One of the key advantages of INCA1 as a drug target is its expression in the nervous system. This makes it a potential target for drugs that can modify the levels of the protein in the brain without affecting its levels in other parts of the body. Additionally, INCA1 is well- conserved across species, which makes it a promising candidate for use in humans.

In addition to its potential as a drug target, INCA1 has also been shown to be a potential biomarker for the diagnosis and monitoring of neurological disorders. The protein is expressed in the brain and has been shown to be involved in the formation of neurofibrillary tangles, which are thought to contribute to the development of Alzheimer's disease.

The discovery and characterization of INCA1 as a potential drug target and biomarker has important implications for the treatment of neurological disorders. If INCA1 is indeed effective in modifying the levels of beta-amyloid in the brain, it could be used to develop new treatments for Alzheimer's disease and other disorders. Additionally, the protein's well-conserved nature makes it a promising candidate for use in humans.

In conclusion, INCA1 (INCA1 variant 1) is a protein that has the potential to be a drug target for the treatment of neurological disorders, including Alzheimer's disease. Its expression in the nervous system and its role in the formation of neurofibrillary tangles make it a promising candidate for use in drugs that can modify the levels of beta-amyloid in the brain. Further research is needed to fully understand the potential of INCA1 as a drug and biomarker.

Protein Name: Inhibitor Of CDK, Cyclin A1 Interacting Protein 1

Functions: Binds to CDK2-bound cyclins and inhibits the kinase activity of CDK2; binding to cyclins is critical for its function as CDK inhibitor (PubMed:21540187). Inhibits cell growth and cell proliferation and may play a role in cell cycle control (By similarity). Required for ING5-mediated regulation of S-phase progression, enhancement of Fas-induced apoptosis and inhibition of cell growth (By similarity)

The "INCA1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about INCA1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets